Citigroup
ENVB icon

Citigroup’s Enveric Biosciences ENVB Stock Holding History

Citigroup’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,276
Closed -$8.26K – 6076
2025
Q4 		$8.26K Buy
+2,276
New +$14.8K ﹤0.01% 5116
2022
Q2 		– Sell
-2
Closed -$6K – 6341
2022
Q1 		$6K Buy
+2
New +$8.84K ﹤0.01% 5744

Other funds holding ENVB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Citigroup's ENVB Position: Q1 2026 in Review

Citigroup sold out of Enveric Biosciences (ENVB) in Q1 2026, closing a stake of 2,276 shares — an estimated $8.26K sold.

Citigroup first reported a position in ENVB in Q1 2022 and held it in 2 quarters. The position peaked at $8.26K in Q4 2025. 11 funds tracked by Wall St. Rank hold ENVB as of Q1 2026.

  • Citigroup reported no remaining Enveric Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 2,276 Enveric Biosciences shares in Q1 2026, an estimated $8.26K.
  • Citigroup first reported a position in Enveric Biosciences in Q1 2022 and held it in 2 quarters.
  • Citigroup's Enveric Biosciences position peaked at $8.26K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.